Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Given Average Rating of “Hold” by Analysts

Shares of Tvardi Therapeutics, Inc. (NASDAQ:TVRD) have received a consensus recommendation of “Hold” from the seven ratings firms that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and three have given a buy recommendation to the company. The average 1-year target price among brokers that have covered the stock in the last year is $55.50.

Several equities research analysts have weighed in on the stock. BTIG Research decreased their price target on shares of Tvardi Therapeutics from $55.00 to $15.00 and set a “buy” rating for the company in a research note on Monday, October 13th. Cantor Fitzgerald downgraded Tvardi Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Monday, October 13th. Piper Sandler lowered Tvardi Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Monday, October 13th. Weiss Ratings reiterated a “sell (e)” rating on shares of Tvardi Therapeutics in a report on Monday, December 29th. Finally, Raymond James Financial cut Tvardi Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Tuesday, October 14th.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. Slate Path Capital LP bought a new stake in shares of Tvardi Therapeutics during the second quarter worth about $16,427,000. 683 Capital Management LLC acquired a new position in Tvardi Therapeutics during the 2nd quarter valued at about $4,107,000. Vestal Point Capital LP acquired a new position in Tvardi Therapeutics during the 3rd quarter valued at about $6,508,000. Geode Capital Management LLC bought a new stake in Tvardi Therapeutics during the 2nd quarter worth approximately $2,617,000. Finally, Invesco Ltd. bought a new stake in Tvardi Therapeutics during the 3rd quarter worth approximately $3,219,000. 44.66% of the stock is currently owned by institutional investors and hedge funds.

Tvardi Therapeutics Stock Performance

Shares of TVRD opened at $4.57 on Friday. The firm has a market cap of $42.87 million, a PE ratio of -0.48 and a beta of 0.09. Tvardi Therapeutics has a 52-week low of $3.74 and a 52-week high of $43.65. The business’s 50 day moving average price is $4.15 and its two-hundred day moving average price is $17.38.

Tvardi Therapeutics (NASDAQ:TVRD) last released its quarterly earnings data on Thursday, November 13th. The company reported ($0.59) earnings per share for the quarter, beating the consensus estimate of ($0.83) by $0.24.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.